Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Issue 7 (26th May 2015)

• Record Type: Journal Article
• Authors: Lundh, M.; Galbo, T.; Poulsen, S. S.; Mandrup‐Poulsen, T.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 7(2015:Jul.)
• Page Start: 703
• Page End: 707
• Publication Date: 2015-05-26
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12470
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12470-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="dom12470-para-0001">Failure of pancreatic β cells to compensate for insulin resistance is a prerequisite for the development of type 2 diabetes. Sustained elevated circulating levels of free fatty acids and glucose contribute to β‐cell failure. Selective inhibition of histone deacetylase (HDAC)‐3 protects pancreatic β cells against inflammatory and metabolic insults <italic>in vitro</italic>. In the present study, we tested the ability of a selective HDAC3 inhibitor, BRD3308, to reduce hyperglycaemia and increase insulin secretion in a rat model of type 2 diabetes. At diabetes onset, an ambulatory hyperglycaemic clamp was performed. HDAC3 inhibition improved hyperglycaemia over the study period without affecting weight gain. At the end of the hyperglycaemic clamp, circulating insulin levels were significantly higher in BRD3308‐treated rats. Pancreatic insulin staining and contents were also significantly higher. These findings highlight HDAC3 as a key therapeutic target for β‐cell protection in type 2 diabetes.</p> </abstract>